These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 3265377)
1. In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations. Jones RN Drugs; 1988; 35 Suppl 7():17-26. PubMed ID: 3265377 [TBL] [Abstract][Full Text] [Related]
2. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination. Jones RN; Barry AL J Clin Microbiol; 1987 Oct; 25(10):1920-5. PubMed ID: 3117843 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of aminopenicillins combined with sulbactam, clavulanic acid, or amdinocillin against bacteria isolated from patients with complicated urinary tract infections. Naber KG; Wittenberger R Rev Infect Dis; 1986; 8 Suppl 5():S604-8. PubMed ID: 3026011 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase]. Moittie D; Simonet M; Veron M Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362 [TBL] [Abstract][Full Text] [Related]
5. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Nomura S; Hanaki H; Nagayama A J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745 [TBL] [Abstract][Full Text] [Related]
6. Implications of beta-lactamase-inhibitor combinations. Fuchs PC; Barry AL J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514 [TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of penicillin G plus sulbactam in comparison with other beta-lactamase inhibitor combinations and oxacillin against staphylococci. Jansen B; Perdreau-Remington F; Pulverer G Zentralbl Bakteriol; 1996 Jul; 284(2-3):297-301. PubMed ID: 8837390 [TBL] [Abstract][Full Text] [Related]
8. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro]. Blahová J; Hupková M; Krcméry V Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760 [TBL] [Abstract][Full Text] [Related]
9. Possible prevention of in vitro selection of resistant Streptococcus pneumoniae by beta-lactamase inhibitors. Carsenti-Etesse H; Durant J; De Salvador F; Bensoussan M; Bensoussan F; Pradier C; Bernard E; Mondain V; Thabaut A; Dellamonica P Eur J Clin Microbiol Infect Dis; 1994 Dec; 13(12):1058-62. PubMed ID: 7889969 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae. Fuchs PC; Barry AL; Pfaller MA; Hardy DJ; McLaughlin JC; Gerlach EH Diagn Microbiol Infect Dis; 1993; 17(2):171-5. PubMed ID: 8243040 [TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Sader HS; Tosin I; Sejas L; Miranda E Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842 [TBL] [Abstract][Full Text] [Related]
12. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae. Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705 [TBL] [Abstract][Full Text] [Related]
13. [In vitro comparison of the beta lactamase-inhibitory action of clavulanic acid and sulbactam in ampicillin-resistant enterobacteria]. Grimm H Arzneimittelforschung; 1987 Oct; 37(10):1116-9. PubMed ID: 3501722 [TBL] [Abstract][Full Text] [Related]
14. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Aronoff SC; Jacobs MR; Johenning S; Yamabe S Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169 [TBL] [Abstract][Full Text] [Related]
15. Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy. Itokazu GS; Danziger LH Pharmacotherapy; 1991; 11(5):382-414. PubMed ID: 1745624 [TBL] [Abstract][Full Text] [Related]
16. Beta-lactamase inhibitors and Acinetobacter spp. Eng RH; Smith SM; Cherubin CE J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200 [No Abstract] [Full Text] [Related]
17. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors. Barry AL; Jones RN; Packer RR J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222 [No Abstract] [Full Text] [Related]
18. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains. Paniagua GL; Monroy E; García O; Vaca S Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741 [TBL] [Abstract][Full Text] [Related]
19. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors. Qadri SM; Ueno Y; Cunha BA Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of in vitro methods for testing susceptibility of anaerobes to ampicillin-sulbactam and amoxicillin-clavulanic acid. Fuchs PC; Barry AL; Jones RN J Clin Microbiol; 1988 Jun; 26(6):1246-7. PubMed ID: 3384939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]